Last year was one of the 'most event­ful in US biosim­i­lars his­to­ry,' but these an­a­lysts say 2022 should be 'a turn­ing point'

Though last year saw few­er mar­ket en­trants in the biosim­i­lar space than years past, Car­di­nal Health still called it one of the “most event­ful” in US biosim­i­lars his­to­ry, ac­knowl­edg­ing sev­er­al key ap­provals that have the po­ten­tial to make a big splash.

“This past year, the promise of biosim­i­lars has start­ed to be­come a re­al­i­ty, as greater com­pe­ti­tion for some of the costli­est bi­o­log­ic treat­ments on the mar­ket is be­gin­ning to dri­ve mean­ing­ful cost sav­ings,” So­nia Os­k­ouei, VP of biosim­i­lars at Car­di­nal, wrote in the com­pa­ny’s re­cent­ly re­leased re­port.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.